Klaus K. Witte

Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of Fallot.

Carvedilol in the treatment of elderly patients with chronic heart failure.

Chronotropic incompetence does not contribute to submaximal exercise limitation in patients with chronic heart failure.

GPs have pivotal role in managing CHF.

Cardiac resynchronisation therapy for chronic heart failure and conduction delay.

Marine polyunsaturated fatty acids in heart failure. Are the theoretical benefits matched by the clinical data?

Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras.

The intramuscular contribution to the slow oxygen uptake kinetics during exercise in chronic heart failure is related to the severity of the condition.

Isolated left ventricular apical hypoplasia evaluated by cardiovascular magnetic resonance and gadolinium enhancement techniques.

A novel cardiopulmonary exercise test protocol and criterion to determine maximal oxygen uptake in chronic heart failure.

Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes.

Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology.

Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction.

Septal pacing: still no clarity?

Pacing-associated left ventricular dysfunction? Think reprogramming first!

Response to (resynchronization) therapy in chronic heart failure: time for a different approach.

Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure.

Micronutrients for chronic heart failure: end of the road or path to enlightenment?

Patients with long-term permanent pacemakers have a high prevalence of left ventricular dysfunction.

Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity.

An evaluation of 20 year survival in patients with diabetes mellitus and acute myocardial infarction.

Ambulatory heart rate range predicts mode-specific mortality and hospitalisation in chronic heart failure.

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke.

Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification.

Effects of Vitamin D on Cardiac Function in Patients With Chronic HF: The VINDICATE Study.

Chronotropic Incompetence Does Not Limit Exercise Capacity in Chronic Heart Failure.

Diabetes mellitus is associated with adverse structural and functional cardiac remodelling in chronic heart failure with reduced ejection fraction.

Submaximal fitness and mortality risk reduction in coronary heart disease: a retrospective cohort study of community-based exercise rehabilitation.

Exercise training: The under developed elixir vitae of chronic disease?

Remote management of heart failure using implantable electronic devices.

Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.

Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes.

Quantitative deformation analysis differentiates ischaemic and non-ischaemic cardiomyopathy: sub-group analysis of the VINDICATE trial.

Rate-Response Programming Tailored to the Force-Frequency Relationship Improves Exercise Tolerance in Chronic Heart Failure.

Devices in heart failure; diagnosis, detection and disease modification.

Socioeconomic deprivation and mode-specific outcomes in patients with chronic heart failure.

Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes.

Reliability and Physiological Interpretation of Pulmonary Gas Exchange by "Circulatory Equivalents" in Chronic Heart Failure.

Therapeutic options for functional mitral regurgitation in chronic heart failure.

Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II.

Commentaries on Viewpoint: V̇o is an acceptable estimate of cardiorespiratory fitness but not V̇o.

Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure.

Prevalence and Predictors of Sepsis Death in Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction.

Ischemic Heart Disease Modifies the Association of Atrial Fibrillation With Mortality in Heart Failure With Reduced Ejection Fraction.

Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care.

Heart failure and right ventricular pacing - how to avoid the need for cardiac resynchronization therapy.

Predicting one-year mortality in heart failure using the 'Surprise Question': a prospective pilot study.

Cardiac magnetic resonance in patients with cardiac resynchronization therapy: is it time to scan with resynchronization on?

Heart failure: A preventable and treatable complication of type 2 diabetes.

Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.

Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II.

Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the UK.

Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial.

Divergent skeletal muscle mitochondrial phenotype between male and female patients with chronic heart failure.

Long-term Outcomes Are Poor in Intravenous Drug Users Following Infective Endocarditis, Even After Surgery.

The REDUCE FMR Trial: A Randomized Sham-Controlled Study of Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation.

Futility in cardiology: the need for a change in perspectives: reply.

Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.

Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.

Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology.

Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM-HF trial.

Cardiac resynchronization therapy following Carillon annuloplasty device for symptomatic heart failure and functional mitral regurgitation: a case report.

Long-Term Survival Following Transcatheter Mitral Valve Repair: Pooled Analysis of Prospective Trials with the Carillon Device.

Prevalence and prognostic significance of device-detected subclinical atrial fibrillation in patients with heart failure and reduced ejection fraction.

Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study.

Infection-Related Hospitalization in Heart Failure With Reduced Ejection Fraction: A Prospective Observational Cohort Study.

Transcatheter indirect mitral annuloplasty induces annular and left atrial remodelling in secondary mitral regurgitation.

Implantable cardioverter-defibrillator therapy to reduce sudden cardiac death in adults with congenital heart disease: A registry study.

Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus.

Dying 'due to' or 'with' COVID-19: a cause of death analysis in hospitalised patients.

Prioritizing symptom management in the treatment of chronic heart failure.

Observational data during the COVID-19 pandemic: opportunity with uncertainty.

Feasibility and validation of trans-valvular flow derived by four-dimensional flow cardiovascular magnetic resonance imaging in pacemaker recipients.

Unique Transcriptome Signature Distinguishes Patients With Heart Failure With Myopathy.

Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction.

Electrical weapons and rhabdomyolysis.

Secondary mitral regurgitation: reducing the leak, expanding the science.

Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology.

Association of heart failure and its comorbidities with loss of life expectancy.

Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".

Closing the loop: Delivering personalised care for patients with cryptogenic stroke.

Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence.

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke.

Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data.

To the Editor-New phones, old problem? Interference with cardiovascular implantable electronic devices by phones containing magnets.

Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study.

Quantifying the relationship and contribution of mitochondrial respiration to systemic exercise limitation in heart failure.

Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial.

Advances in cardiac resynchronization and implantable cardioverter/defibrillator therapy: Medtronic Cobalt and Crome.

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction.

Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study.

Brown and beige adipose tissue regulate systemic metabolism through a metabolite interorgan signaling axis.

Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.

Detrimental Immediate- and Medium-Term Clinical Effects of Right Ventricular Pacing in Patients With Myocardial Fibrosis.

Sexual dimorphism in adipose tissue mitochondrial function and metabolic flexibility in obesity.

Impact of the COVID-19 pandemic on the management of chronic heart failure.

Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure.

Suboptimal Dosing of β-Blockers in Chronic Heart Failure: A Missed Opportunity?

We Do Not Talk to Patients About Their Prognosis, But Is Any of This Surprising?

Cost-effectiveness of insertable cardiac monitors for diagnosis of atrial fibrillation in cryptogenic stroke in Australia.

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes.

Causes of Death in People With Cardiovascular Disease: A UK Biobank Cohort Study.

Heart rate, exercise capacity, and the force-frequency relationship in chronic heart failure.

Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial.

Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation.

An enormous right atrial myxoma highlights the role of echocardiography in heart failure pathways: a case report.

Diabetes mellitus and the causes of hospitalisation in people with heart failure.

Long-chain ceramides are cell non-autonomous signals linking lipotoxicity to endoplasmic reticulum stress in skeletal muscle.

Cardiac resynchronisation therapy with or without a defibrillator: individualising device prescription.

Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?

Systemic Inflammation Is Associated With Future Risk of Fatal Infection: An Observational Cohort Study.

Surgical Techniques and Outcomes in Patients With Intra-Cardiac Abscesses Complicating Infective Endocarditis.

Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction.

Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure.

Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes.

Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.

'Acute Heart Failure': Should We Abandon the Term Altogether?

Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK.

Clinical implications and risk factors for QRS prolongation over time in heart failure patients.

Cardiomyopathy Associated with Right Ventricular Apical Pacing-Systematic Review and Meta-Analysis.

Correction: Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data.

Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US.

Remote monitoring in heart failure: it's the data you collect what you do with them.

Atrial secondary mitral regurgitation: prevalence, characteristics, management, and long-term outcomes.

It's a Matter of Fat: The Obesity Paradox in Heart Failure.

Outcomes following cardiac resynchronisation therapy in older people.

Potential role of pregabalin in the treatment of episodic breathlessness.

Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction.